


Author's Accepted Manuscript

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis

Emer Fogarty, Susanne Schmitz, Niall Tubridy, Cathal Walsh, Michael Barry



PII: S2211-0348(16)30087-6
DOI: <http://dx.doi.org/10.1016/j.msard.2016.06.001>
Reference: MSARD414

To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 24 April 2015
Revised date: 29 April 2016
Accepted date: 7 June 2016

Cite this article as: Emer Fogarty, Susanne Schmitz, Niall Tubridy, Cathal Walsh and Michael Barry, Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis, *Multiple Sclerosis and Related Disorders* <http://dx.doi.org/10.1016/j.msard.2016.06.001>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain

Title:

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis

Authors:

1. Emer Fogarty PhD, National Centre for Pharmacoeconomics, Dublin, Ireland
2. Susanne Schmitz PhD, Department of Pharmacology and Therapeutics, Trinity College Dublin, Ireland.
3. Niall Tubridy MB, Department of Neurology, St. Vincent's University Hospital, Dublin, Ireland.
4. Cathal Walsh PhD, Department of Mathematics and Statistics, University of Limerick, Ireland.
5. Michael Barry MB, National Centre for Pharmacoeconomics, Dublin, Ireland.

Corresponding author:

Emer Fogarty PhD
efogarty@stjames.ie
Tel: + 353 1 4103427
Fax: + 353 1 4730596

Abstract**Introduction**

Randomised studies have demonstrated efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis (RRMS). However it is unclear how the magnitude of treatment efficacy varies across all currently available therapies.

Objective

To perform a systematic review and network meta-analysis to evaluate the comparative efficacy of available therapies in reducing relapses and disability progression in RRMS.

Methods

A systematic review identified 28 randomised, placebo-controlled and direct comparative trials. A network meta-analysis was conducted within a Bayesian framework to estimate comparative annualised relapse rates (ARR) and risks of disability progression (defined by both a 3-month, and 6-

Download English Version:

<https://daneshyari.com/en/article/5912076>

Download Persian Version:

<https://daneshyari.com/article/5912076>

[Daneshyari.com](https://daneshyari.com)